Behavioral health and addiction treatment facilities are valued primarily on EBITDA multiples adjusted for payer composition, occupancy stability, and regulatory standing. A treatment center's EBITDA represents annual revenue minus direct operating costs like clinical staffing, medications, supplies, and facility expenses, as well as indirect costs such as billing, administration, and management overhead, but before deducting interest on debt or owner distributions.

The starting point for any treatment center valuation is adjusted EBITDA. A 40-bed residential facility generating $3.2M in annual revenue with 60% direct costs and 22% indirect costs produces roughly $576K in adjusted EBITDA, or an 18% margin. That same facility at $4.0M revenue through improved occupancy and payer optimization could reach $800K EBITDA. PE buyers typically apply 10x-13x multiples to well-documented, stable EBITDA, while hospital system acquirers apply 7x-10x because they capture integration synergies through consolidated billing and shared overhead.

Payer mix is the dominant variable in treatment center valuation. Commercial insurance reimburses at $250-450 per patient-day depending on the level of care and geographic market. Medicaid reimburses $80-150 per patient-day. Self-pay collections, after typical write-off rates of 40-50%, yield $60-120 per patient-day. A 60-bed facility operating at 85% occupancy with a 90-day average length of stay and 75% commercial payer mix generates materially different revenue than the same facility at 55% commercial. The revenue gap between those two payer profiles can reach $400K-700K annually, which at 10x EBITDA multiples translates to $4M-7M in enterprise value difference. Buyers model payer-mix sensitivity over five-year horizons and apply risk discounts to Medicaid-dominant facilities because government reimbursement rates face legislative uncertainty.

Census and occupancy function as the stability metric buyers trust most. Facilities maintaining 85% or higher average daily occupancy for 18-plus consecutive months demonstrate consistent referral pipelines, effective marketing, and community reputation strength. Occupancy below 70% triggers turnaround pricing from buyers, who assume 6-12 months of operational improvement before stabilization and apply discounted multiples of 6x-8x instead of 10x-13x. Seasonal patterns are expected in many markets, but unexplained occupancy declines trending from 85% down to 65% over 12 months signal referral loss, quality reputation damage, or new competitor entry that can reduce valuations 25-40%.

Licensing and accreditation create valuation floors and ceilings. State-licensed facilities without CARF or Joint Commission accreditation typically receive 7x-9x EBITDA multiples regardless of other metrics. Accredited facilities consistently achieve 10x-14x multiples because accreditation serves as a proxy for clinical governance, staff training infrastructure, and payer network access. Payers increasingly require accreditation for in-network participation, which means non-accredited facilities face shrinking referral volumes over time. Facilities with any licensing violations, failed surveys, or active regulatory investigations in the prior 36 months face 25-40% valuation reductions. PE buyers conduct regulatory diligence through state board records and complaint histories before issuing letters of intent.

Outcomes data has become a material valuation factor in recent years. Readmission rates, treatment completion percentages, patient satisfaction scores, and discharge disposition metrics allow buyers to validate clinical effectiveness and project payer relationship strength. Facilities with 18-plus months of audited, third-party-validated outcomes data reduce buyer diligence risk and typically accelerate transaction timelines by four to eight weeks. Benchmarking outcomes against SAMHSA reporting standards demonstrates clinical credibility. Facilities that cannot produce outcomes documentation face buyer skepticism about treatment quality and justify lower multiples—typically 8x-10x versus 11x-14x for well-documented competitors.

Clinical team composition and stability represent a core risk factor. Facilities where a single medical director or founder-clinician controls clinical decision-making and patient relationships face 30-50% valuation reductions due to key-person dependency. PE acquirers require documented clinical org charts, succession plans, and retention data. Staff turnover above 25% annually across clinical positions signals compensation issues or burnout culture. Facilities with average clinical staff tenure of five-plus years earn confidence premiums because buyers model post-acquisition staff retention as a critical integration risk. On-site medical directors are required for detox licensure and are non-negotiable in buyer diligence.

The buyer landscape for behavioral health facilities includes several distinct categories. Healthcare-focused PE firms investing $5M-50M per platform acquisition seek EBITDA scalability and multi-site consolidation opportunities, typically paying 10x-14x for well-positioned platforms. Hospital systems acquiring outpatient treatment capacity to complement inpatient behavioral health units generally pay 7x-10x because they capture cost synergies internally. National treatment networks like Acadia Healthcare or Universal Health Services acquire to expand geographic coverage and add bed capacity, paying 9x-12x depending on strategic fit. Physician management groups seeking to add behavioral health to multi-specialty platforms round out the buyer pool. Each buyer type applies different multiples to identical EBITDA based on strategic rationale, integration costs, and growth assumptions.